All News

"Test and treat" scheme reducing stress on general practitioners. 

The program increased hypertension management rates to 77% in 2017. 

Tom Kraus to bring expeirence in government and industry.

Two Arizona pharmacists made headlines when it seems they may have not adhered to the Oath of the Pharmacist.

Success depends on marketing, relationship building. 

Solriamfetol is approved for adult patients suffering from the effects of narcolepsy and OSA. 

The CBD market is anticipated to be worth $20 billion by 2024.

New guide details actions for pharmacists and payers.

 More than 25,000 lawsuits cite uncontrollable and irreversible bleeding and death. 

Patients taking PPIs 28.4 times more likely to develop chronic kidney disease. 

The groups say the state has intentionally suppressed dispensing fees to reimburse pharmacies that service Medicaid patients.

Effective management strategies are needed for medications billed through medical benefits.

Researchers targeting virus' receptors used to enter the body. 

First drug approved for PPD use to remain under REMS program.

Grief: An under-recognized reality that deserves serious attention. 

CHPA says over $146 billion and countless productivity hours are saved by the availability and accessibility of OTC medications and products. 

The free course will cover a myraid of drug policy issues. 

"Our jobs change, our families change, our kids change, and whether we realize it or not, we change."

Ensure quality by achieving and maintaining competence to administer immunizations. 

Survey shows pharmacists are eager to provide care for the whole patient continuum. 

Aggregated data highlights manufacturers responsible for price increases. 

Study finds different anticoagulation treatment levels for patients with cognitive problems.

A meta-analysis of 95 studies indicates lower risk of stroke and intracranial hemorrhage.

Beginning January 2020, all new employer clients must incorporate Point-of-Sale discounts.

Between 34.6% and 55.4% of patients prescribed TIRF were opioid-intolerant